International journal of dermatology · 2017
Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vinay Keshavamurthy, Yanamandra Uday, Dogra Sunil, Handa Sanjeev, Suri Vikas, Kumari Savita, Khadwal Alka, Prakash Gaurav, Lad Deepesh, Varma Subhash, Malhotra Pankaj
Аннотация
BACKGROUND: Short-term mucocutaneous adverse effects are well documented with imatinib. However, studies on long-term adverse effects and in the ethnic population are lacking.
OBJECTIVE: To study the long-term mucocutaneous adverse effects of imatinib and factors predicting these adverse effects.
METHODS: In this cross-sectional study, consenting adult chronic myeloid leukemia patients on imatinib for more than 250 days were recruited. The details of imatinib treatment were retrieved from hematology clinic records.
RESULTS: Four hundred and thirty-eight patients who were on imatinib for a mean duration of 1820 days were recruited. A mean number of 1.42 ± 0.98 cutaneous adverse effects were seen per patient. Melasma-like pigmentation, periorbital edema, oral lichenoid reaction, cutaneous hypopigmentation, and vesicobullous eruptions were seen in 236 (53.9%), 81 (18.5%), 70 (16%), 42 (9.6%), and 12 (2.7%) patients, respectively. Drug-induced cutaneous eruptions (9.1%) and cutaneous hypopigmentation (9.6%) were seen less frequently. Cutaneous hyperpigmentation was more likely seen in younger patients (P = 0.001) and females (P < 0.001). On multivariate analysis, female gender was a significant risk factor for developing cutaneous hyperpigmentation and periorbital edema.
CONCLUSION: Cutaneous hyperpigmentation and periorbital edema are common long-term adverse effects of imatinib in Indian patients. Female gender is a significant risk factor for the development of both these adverse effects.
OBJECTIVE: To study the long-term mucocutaneous adverse effects of imatinib and factors predicting these adverse effects.
METHODS: In this cross-sectional study, consenting adult chronic myeloid leukemia patients on imatinib for more than 250 days were recruited. The details of imatinib treatment were retrieved from hematology clinic records.
RESULTS: Four hundred and thirty-eight patients who were on imatinib for a mean duration of 1820 days were recruited. A mean number of 1.42 ± 0.98 cutaneous adverse effects were seen per patient. Melasma-like pigmentation, periorbital edema, oral lichenoid reaction, cutaneous hypopigmentation, and vesicobullous eruptions were seen in 236 (53.9%), 81 (18.5%), 70 (16%), 42 (9.6%), and 12 (2.7%) patients, respectively. Drug-induced cutaneous eruptions (9.1%) and cutaneous hypopigmentation (9.6%) were seen less frequently. Cutaneous hyperpigmentation was more likely seen in younger patients (P = 0.001) and females (P < 0.001). On multivariate analysis, female gender was a significant risk factor for developing cutaneous hyperpigmentation and periorbital edema.
CONCLUSION: Cutaneous hyperpigmentation and periorbital edema are common long-term adverse effects of imatinib in Indian patients. Female gender is a significant risk factor for the development of both these adverse effects.
Предметные рубрики MeSH
AdolescentAdultAge FactorsAgedAntineoplastic AgentsCross-Sectional StudiesDrug EruptionsEdemaEye DiseasesFemaleHumansHyperpigmentationHypopigmentationImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLichenoid EruptionsMaleMiddle AgedMouth DiseasesMouth MucosaNail DiseasesSex FactorsSkin Diseases, VesiculobullousTime FactorsYoung Adult